Ettore D'Argento

IRCCS Fondazione Policlinico Universitario A. Gemelli

Emailettore.dargento@policlinicogemelli.it

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Ettore D'Argento is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

6 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or

26 Article
3 Review article
1 Editorial

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Cortellini, A., Di Maio, M., Nigro, O., Leonetti, A., Cortinovis, D. L., Aerts, J. G. J. V., Guaitoli, G., Barbieri, F., Giusti, R., Ferrara, M. G., Bria, E., D'Argento, E., Grossi, F., Rijavec, E., Guida, A., Berardi, R., Torniai, M., Sforza, V., Genova, C., Mazzoni, F. & 30 others, Garassino, M. C., De Toma, A., Signorelli, D., Gelibter, A., Siringo, M., Marchetti, P., MacErelli, M., Rastelli, F., Chiari, R., Rocco, D., Della Gravara, L., Inno, A., Michele, D. T., Grassadonia, A., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Santini, D., Citarella, F., Russano, M., Cantini, L., Tuzi, A., Bordi, P., Minuti, G., Landi, L., Ricciardi, S., Migliorino, M. R., Passiglia, F. & Russo, A., Apr 7 2021, In: Journal for ImmunoTherapy of Cancer. 9, 4, e002421.
Research output: Contribution to journal › Article › peer-review

Open Access
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
Cortellini, A., Cannita, K., Tiseo, M., Cortinovis, D. L., Aerts, J. G. J. V., Baldessari, C., Giusti, R., Ferrara, M. G., D'Argento, E., Grossi, F., Guida, A., Berardi, R., Morabito, A., Genova, C., Antonuzzo, L., Mazzoni, F., De Toma, A., Signorelli, D., Gelibter, A., Targato, G. & 30 others, Rastelli, F., Chiari, R., Rocco, D., Gori, S., De Tursi, M., Mansueto, G., Zoratto, F., Filetti, M., Bracarda, S., Citarella, F., Marco, R., Cantini, L., Nigro, O., Buti, S., Minuti, G., Landi, L., Ricciardi, S., Migliorino, M. R., Natalizio, S., Simona, C., De Filippis, M., Metro, G., Adamo, V., Russo, A., Spinelli, G. P., Di Maio, M., Banna, G. L., Friedlaender, A., Addeo, A. & Pinato, D. J., May 2021, In: European Journal of Cancer. 148, p. 24-35 12 p.
Research output: Contribution to journal › Article › peer-review
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
Cortellini, A., De Giglio, A., Cannita, K., Cortinovis, D. L., Cornelissen, R., Baldesarri, C., Giusti, R., D'Argento, E., Grossi, F., Santoni, M., Catino, A., Berardi, R., Sforza, V., Rossi, G., Antonuzzo, L., Di Noia, V., Signorelli, D., Gelibter, A., Occhipinti, M. A., Follador, A. & 31 others, Rastelli, F., Chiari, R., Gravara, L. D., Inno, A., De Tursi, M., Di Marino, P., Mansueto, G., Zoratto, F., Filetti, M., Montrone, M., Citarella, F., Pensieri, M. V., Russano, M., Cantini, L., Nigro, O., Leonetti, A., Bordi, P., Minuti, G., Landi, L., De Toma, A., Donisi, C., Ricciardi, S., Migliorino, M. R., Napoli, V. M., Leone, G., Metro, G., Banna, G. L., Friedlaender, A., Addeo, A., Ficorella, C. & Porzio, G., 2021, (Accepted/In press) In: Thoracic Cancer.
Research output: Contribution to journal › Article › peer-review

Open Access
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
Di Noia, V., D’Argento, E., Pilotto, S., Vita, E., Ferrara, M. G., Damiano, P., Ribelli, M., Cannella, A., Virtuoso, A., Fattorossi, A., Ceresoli, G. L., Milella, M., Beretta, G. D., Tortora, G. & Bria, E., 2020, (Accepted/In press) In: Cancer Immunology, Immunotherapy.
Research output: Contribution to journal › Article › peer-review

Open Access
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study
study, CLARITY., Bersanelli, M., Buti, S., Giannarelli, D., Leonetti, A., Cortellini, A., Russo, G. L., Signorelli, D., Toschi, L., Milella, M., Pilotto, S., Bria, E., Proto, C., Marinello, A., Randon, G., Rossi, S., Vita, E., Sartori, G., D'Argento, E., Qako, E. & 31 others, Giaiacopi, E., Ghilardi, L., Bettini, A. C., Rapacchi, E., Mazzoni, F., Lavacchi, D., Scotti, V., Ciccone, L. P., De Tursi, M., Di Marino, P., Santini, D., Russano, M., Bordi, P., Di Maio, M., Audisio, M., Filetti, M., Giusti, R., Berardi, R., Fiordoliva, I., Cerea, G., Pizzutilo, E. G., Bearz, A., De Carlo, E., Cecere, F., Renna, D., Camisa, R., Caruso, G., Ficorella, C., Banna, G. L., Cortinovis, D. & Garassino, M. C., Dec 2020, In: Lung Cancer. 150, p. 123-131 9 p.
Research output: Contribution to journal › Article › peer-review

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study

Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study